Department of Oncology, Augustin Morvan Hospital, Brest University Hospital, Brest, France.
Department of Pulmonology, Annecy Genevois Hospital, Annecy, France.
Thorac Cancer. 2021 Apr;12(8):1240-1243. doi: 10.1111/1759-7714.13862. Epub 2021 Feb 23.
Durvalumab is a humanized monoclonal antibody targeting programmed cell death ligand-1 (PD-L1), leading to an antitumor activity, used as consolidation therapy in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). Several immune-related adverse events (irAEs) have previously been described in patients following treatment with immune checkpoint inhibitors (ICIs). To the best of our knowledge, we report the first case of immunotherapy-induced fully reversible bronchiolitis and bronchiectasis, despite the fact that its pathophysiological mechanism has been previously considered to be irreversible.
度伐利尤单抗是一种针对程序性死亡配体 1（PD-L1）的人源化单克隆抗体，具有抗肿瘤活性，用于局部晚期不可切除的非小细胞肺癌（NSCLC）患者的巩固治疗。在接受免疫检查点抑制剂（ICI）治疗的患者中，此前曾描述过几种免疫相关不良事件（irAE）。据我们所知，我们报告了首例免疫治疗引起的完全可逆性细支气管炎和支气管扩张症的病例，尽管其病理生理学机制此前被认为是不可逆转的。
